Sarepta Therapeutics Inc.: Mixed — EPS $0.13, Revenue $381.4M
Mixed ResultQ3 2026 · After-market
Did Sarepta Therapeutics Inc. (SRPT) beat earnings?
It was a mixed report for Q3 2026 — Sarepta Therapeutics Inc. (SRPT) beat on revenue but missed on EPS.
Earnings Per Share-63.89% surprise
$0.13Actual
Expected: $0.36
vs. year ago +200.0%
Total Revenue+8.94% surprise
$381.4MActual
Expected: $350.1M
vs. year ago -5.0%
Released Nov 05 · 4:05 PM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $381.40M | $399.40M | -5.0 |
| Revenue detail — reported lines | |||
| └─PMO net product revenues | ~$240.3M | - | - |
| └─ELEVIDYS net product revenue | $83.50M | - | - |
| Net Loss | ($28.50M) | ($50.60M) | -44.0 |
| GAAP Diluted EPS | -$0.27 | -$0.50 | -46.0 |
| Non-GAAP Diluted EPS | $0.13 | -$0.13 | - |
Financial Outlook / Guidance
| Metric | FY2026 Outlook |
|---|---|
| Guidance | |
| Total net product revenue | $1.25B-$1.3B |
| Non-GAAP R&D and SG&A expenses | $800M-$825M |
FY2026 Outlook
- Total net product revenue
- Guidance$1.25B-$1.3B
- Non-GAAP R&D and SG&A expenses
- Guidance$800M-$825M
Business Highlights
- ➤SRP-1003 and SRP-1001 multiple ascending-dose data are expected in Q4 2026.
- ➤Company is preparing both DM1 and FSHD programs for Phase 3 development.
- ➤Clinical-supply manufacturing has begun for the DM1 and FSHD programs.
- ➤SRP-1003 preclinical data showed dose-dependent nuclear and cytoplasmic DMPK knockdown.
- ➤SRP-1003 data showed correction of MBNL-dependent mis-splicing in preclinical studies.
- ➤ELEVIDYS data in ambulatory patients aged 8-12 showed two-year benefit versus external controls.
- ➤ELEVIDYS data in patients treated at ages 2-3 showed dystrophin expression and sarcolemmal localization.
- ➤Initial Phase 4 ENDURE results evaluated approaches to liver-safety risk mitigation.
Management Commentary
Michael Severino, M.D., chief executive officer, Sarepta
“After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential to deliver differentiated medicines, and the financial strength to invest in our highest-value opportunities.”
Michael Severino, M.D., chief executive officer, Sarepta
“This quarter, we saw continued strength in our commercial execution. Our upcoming DM1 and FSHD datasets are important opportunities to demonstrate the depth of knockdown and downstream biological effects we believe our platform can achieve. We are already preparing both programs for potential late-stage development with the intent of moving efficiently if the results support advancement. We have work to do, and I want us to be measured by execution, but I believe Sarepta has the commercial foundation, pipeline opportunities and financial strength to deliver meaningful long-term value.”